Sugi Predict

Sugi Predict / Compounds / SCHEMBL2145671

SCHEMBL2145671

SCHEMBL2145671

CCCCCCCCCCCCCCCC(=O)OCI

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DGKA P23743 1/20 0.69
▸ PAM P19021 2/20 0.62
▸ TSHR P16473 2/20 0.58
▸ MAPT P10636 1/20 0.58
▸ LMNA P02545 4/20 0.56
▸ DNM1 Q05193 1/20 0.56
▸ ALDH1A1 P00352 1/20 0.56
▸ KDM4E B2RXH2 1/20 0.55
▸ DUSP3 P51452 1/20 0.55
▸ MEN1 O00255 1/20 0.55
▸ KMT2A Q03164 1/20 0.55
▸ PRSS1 P07477 1/20 0.53
▸ PRSS2 P07478 1/20 0.53
▸ PRSS3 P35030 1/20 0.53
▸ CYP3A4 P08684 1/20 0.52
▸ ATM Q13315 1/20 0.52
▸ TDP1 Q9NUW8 1/20 0.52
▸ PRKCA P17252 1/20 0.51
▸ PRKCE Q02156 1/20 0.51
▸ PRKCQ Q04759 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2181324 1.00 DGKA (0.69) DGKAPAMTSHRMAPTLMNA
SCHEMBL2217057 1.00 DGKA (0.69) DGKAPAMTSHRMAPTLMNA
SCHEMBL2182828 1.00 DGKA (0.69) DGKAPAMTSHRMAPTLMNA
SCHEMBL2183449 1.00 DGKA (0.69) DGKAPAMTSHRMAPTLMNA
SCHEMBL355564 1.00 DGKA (0.69) DGKAPAMTSHRMAPTLMNA
SCHEMBL6893576 0.98 DGKA (0.65) DGKAPAMTSHRMAPTLMNA
Chloroform SCHEMBL8307778 0.92 DGKA (0.60) DGKAPAMTSHRMAPTLMNA
SCHEMBL8680864 0.91 — —
Chloroform SCHEMBL8310130 0.90 DGKA (0.57) DGKAPAMTSHRMAPTLMNA
SCHEMBL19193404 0.89 DGKA (0.61) DGKAMAPTLMNADUSP3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114126615-B Opioid receptor antagonist prodrugs 尼萨姆实验室公司 2024-12-31 — — CN disclosed
EP-3965765-A1 OPIOID RECEPTOR ANTAGONIST PRODRUGS Nirsum Laboratories, Inc. (US) 2022-03-16 — — EP disclosed
CN-114126615-A Opioid receptor antagonist prodrugs 尼萨姆实验室公司 2022-03-01 — — CN disclosed
WO-2020223894-A1 OPIOID RECEPTOR ANTAGONIST PRODRUGS NIRSUM LABORATORIES, INC. (US) 2020-11-12 — — WO disclosed
US-10544154-B2 Opioid receptor antagonist prodrugs NIRSUM LABORATORIES, INC. (US) 2020-01-28 — — US disclosed
US-20190307743-A1 OPIOID RECEPTOR ANTAGONIST PRODRUGS NIRSUM LABORATORIES, INC. 2019-10-10 — — US disclosed
US-20190308989-A1 OPIOID RECEPTOR ANTAGONIST PRODRUGS NIRSUM LABORATORIES, INC. 2019-10-10 — — US disclosed
US-20190308988-A1 OPIOID RECEPTOR ANTAGONIST PRODRUGS NIRSUM LABORATORIES, INC. 2019-10-10 — — US disclosed
EP-2521711-B1 QUATERNARY AMMONIUM SALT PRODRUGS ALKERMES PHARMA IRELAND LTD (IE) 2017-08-16 — — EP disclosed
WO-2017132281-A1 METHOD FOR PREPARING AND PRESERVING SANITIZED PRODUCTS APEEL TECHNOLOGY, INC. (US) 2017-08-03 — — WO disclosed
WO-2011084846-A1 QUATERNARY AMMONIUM SALT PRODRUGS ALKERMES, INC. (US) 2011-07-14 — — WO disclosed
WO-2011084848-A2 PRODRUGS OF HETERAROMATIC COMPOUNDS ALKERMES, INC. (US) 2011-07-14 — — WO disclosed
WO-2011084850-A1 PRODRUGS FOR THE TREATMENT OF SCHIZOPHRENIA AND BIPOLAR DISEASE ALKERMES, INC. (US) 2011-07-14 — — WO disclosed
US-20110166194-A1 Asenapine Prodrugs ALKERMES, INC. (US) 2011-07-07 — — US disclosed
US-20110166156-A1 Prodrugs for the Treatment of Schizophrenia and Bipolar Disease ALKERMES, INC. (US) 2011-07-07 — — US disclosed
US-5243043-A Cephalosporin antibiotics and bactericides ROUSSEL UCLAF (FR) 1993-09-07 — — US disclosed
US-4992431-A Bactericides or antibiotics ROUSSELUCLAF (FR) 1991-02-12 — — US disclosed
EP-0105459-B1 SYN-ISOMER OF 7-SUBSTITUTED-3-VINYL-3-CEPHEM COMPOUNDS, PROCESSES FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1989-03-22 — — EP disclosed
US-4559334-A MICROBIOCIDES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1985-12-17 — — US disclosed
EP-0105459-A2 Syn-isomer of 7-substituted-3-vinyl-3-cephem compounds, processes for production thereof and pharmaceutical compositions containing them FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1984-04-18 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190308989-A1 OPIOID RECEPTOR ANTAGONIST PRODRUGS OPRM1, OPRK1, OPRL1 DGKA 3963/4885PAM 192/4885TSHR 473/4885
US-20190307743-A1 OPIOID RECEPTOR ANTAGONIST PRODRUGS OPRM1, OPRK1, OPRL1 DGKA 3963/4885PAM 192/4885TSHR 473/4885
US-20110166194-A1 Asenapine Prodrugs GRIN1, SCN1B, GRIN2B DGKA 2898/4885PAM 1762/4885TSHR 520/4885
US-10544154-B2 Opioid receptor antagonist prodrugs OPRM1, OPRK1, OPRL1 DGKA 3963/4885PAM 192/4885TSHR 473/4885
US-20190308988-A1 OPIOID RECEPTOR ANTAGONIST PRODRUGS OPRM1, OPRK1, OPRL1 DGKA 3963/4885PAM 192/4885TSHR 473/4885
US-20110166156-A1 Prodrugs for the Treatment of Schizophrenia and Bipolar Disease SLC1A2, BDNF, MAOB DGKA 2298/4885PAM 1487/4885TSHR 1502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.